Consortium advances multidisciplinary program for colon cancer

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 2
Volume 18
Issue 2

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. According to the most recent data from NCI, the relative five-year survival rate among metastatic colorectal cancer patients is 8%. While colorectal cancer can metastasize to other organs, including the lung, the liver is the most frequent site of metastasis. Metastases to the liver occur in approximately 50% of colorectal cancer patients and account for at least two-thirds of all colorectal cancer deaths.

ABSTRACT: Statement of support by eight colon cancer advocacy groups calls for more research, reevaluation of criteria for liver resection.

Colorectal cancer is the second leading cause of cancer-related deaths in the United States. According to the most recent data from NCI, the relative five-year survival rate among metastatic colorectal cancer patients is 8%. While colorectal cancer can metastasize to other organs, including the lung, the liver is the most frequent site of metastasis. Metastases to the liver occur in approximately 50% of colorectal cancer patients and account for at least two-thirds of all colorectal cancer deaths.

Research at leading cancer care institutions has shown that a multidisciplinary approach to treating metastatic colorectal cancer results in the best outcomes. A team of medical specialists would consist of: a liver surgeon, a medical oncologist, a radiation oncologist, a gastroenterologist, an oncology nurse, and an oncology social worker. This group would work as one integrated team to offer the best treatment options and care for patients. By combining several types of treatment, these care providers are making it possible for more patients with liver metastases to undergo resection.

While in many large institutions a multidisciplinary team approach is standard practice in treating colorectal cancer, in other settings patients may need to take an active role in enlisting their own team of specialists.

As representatives of oncology patient advocacy organizations, we are committed to furthering a multidisciplinary treatment approach to colorectal cancer. To help make multidisciplinary treatment more accessible, we support the efforts highlighted in the table below. We trust that the commitment of this group of professionals and lay people dedicated to oncology will amplify the potential for advancing multidisciplinary treatment. 

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
Those being treated for peritoneal carcinomatosis may not have to experience the complication rates or prolonged recovery associated with surgical options.
For patients with peritoneal carcinomatosis, integrating PIPAC into a treatment regimen does not interrupt their systemic therapy.
According to Benjamin J. Golas, MD, PIPAC could be used as a bridging therapy before surgical debulking or between subsequent large surgical operations.
According to Benjamin Golas, MD, PIPAC is emerging as minimally invasive laparoscopic approach for patients with peritoneal carcinomatosis.
According to Ronan J. Kelly, deciding whether to give nivolumab- or durvalumab-based regimens in gastric cancers may rely on a patient’s frailty.
Five-year follow-up revealed that patients treated with nivolumab vs placebo in the phase 3 CheckMate 577 trial experienced a “doubling” of survival.
Patients treated with nivolumab in the phase 3 CheckMate 577 trial were less likely to experience progression-related treatment discontinuation vs placebo.
Testing a patient’s genetics may influence decisions such as using longer courses of radiotherapy, says Rachit Kumar, MD.
Spatial transcriptomics and multiplex immunohistochemistry from samples may elucidate outcomes for patients who undergo surgical care for cancer.